Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas (lpr) mice
HJ Anders, E Belemezova, V Eis… - Journal of the …, 2004 - journals.lww.com
Slowly progressive renal injury is the major cause for ESRD. The model of progressive
immune complex glomerulonephritis in autoimmune MRL lpr/lpr mice was used to evaluate
whether chemokine receptor CCR1 blockade late in the disease course can affect
progression to renal failure. Mice were treated with subcutaneous injections of either vehicle
or BX471, a nonpeptide CCR1 antagonist, three times a week from week 20 to 24 of age.
BX471 improved blood urea nitrogen levels (BX471, 35.1±5.3; vehicle, 73.1±39.6 mg/dl; P< …
immune complex glomerulonephritis in autoimmune MRL lpr/lpr mice was used to evaluate
whether chemokine receptor CCR1 blockade late in the disease course can affect
progression to renal failure. Mice were treated with subcutaneous injections of either vehicle
or BX471, a nonpeptide CCR1 antagonist, three times a week from week 20 to 24 of age.
BX471 improved blood urea nitrogen levels (BX471, 35.1±5.3; vehicle, 73.1±39.6 mg/dl; P< …